Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARDIA-STIFF: Dapagliflozin in HFpEF With Type 2 Diabetes
2019-002046-20Phase 4Active
- Sponsor
- FibMed
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (T2DM) comparing Dapagliflozin 10 mg with Placebo (2 arms). Primary endpoint: Change in LV stiffness constant (S+) at peak effort from baseline to 12 months. Started Oct 2019; status: active.
02
Drugs
dapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2019-002046-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002046-20.